Lyramid Ltd and KineraLtd would themselves commercialise their IP including Advangen paying either as applicable for its Midkine for its Evolis range. The present "lifeline" would not be severed. Any other funding if required would be on commercial terms. However, the subsidiaries were never meant to bleed Cellmid. Good point Hobbit2233 I hope I've answered.
Lyramid Ltd and KineraLtd would themselves commercialise their...
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.002(28.6%) |
Mkt cap ! $4.152M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 0.9¢ | $77.73K | 5.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3319000 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 227450 | 2 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.9¢ |
Change
0.002 ( 43.8 %) |
||||
| Open | High | Low | Volume | ||
| 1.4¢ | 1.4¢ | 0.9¢ | 609000 | ||
| Last updated 15.49pm 24/05/2024 ? | |||||
| AN1 (ASX) Chart |